Plant Name: Vigna angularis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; DRD4; | |
| NPSR1; CXCR1; NMUR2; | |
| ALPL; RECQL; TDP1; PLA2G1B; PKM; HKDC1; PIK3CA; PIK3CB; PIK3R1; GLO1; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; NQO2; ALDH1A1; ALOX12; GFER; NOX4; USP2; PYGL; APEX1; POLB; | |
| PTPN1; | |
| ACHE; GAA; | |
| PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; AXL; NEK2; FLT3; NEK6; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; KDR; | |
| CA12; CA7; CA3; CA14; CA5B; CA5A; CA9; CA13; CA4; CA6; CA2; CA1; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
| MMP13; MMP3; MMP2; MMP9; MMP1; | |
| BACE1; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| SLC6A2; | |
| LMNA; MAPT; HTT; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.281E-12 | 5.164E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.211E-12 | 1.185E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.770E-11 | 8.494E-09 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, HKDC1, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIK3CA, PIK3CB, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.418E-11 | 1.034E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.081E-10 | 2.871E-08 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, MMP1, MMP13, MMP2, MMP3, MMP9, NQO2, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.492E-10 | 1.346E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.928E-10 | 1.598E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.463E-09 | 2.722E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.458E-09 | 4.150E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 5.105E-09 | 7.614E-07 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3CA, PIK3CB, PIK3R1, SRC |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.661E-09 | 1.316E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.008E-08 | 1.363E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIK3CA, PIM1, PKN1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.253E-08 | 2.869E-06 | AURKB, CA2, CA7, HIF1A, HTT, MAPK1, NEK2, NPSR1, PIK3CB, PLA2G1B, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.860E-08 | 3.579E-06 | AKT1, ALPL, APEX1, APP, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NFKB1, NOX4, PTGS2, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 8.408E-08 | 9.738E-06 | AXL, KDR, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 8.831E-08 | 1.002E-05 | ABCC1, ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, ALK, ALOX12, ALOX15, ALPL, APP, AXL, BACE1, CA12, CA14, CA2, CA4, CA9, CAMK2B, CSNK2A1, CXCR1, DAPK1, DRD4, ESR1, FLT3, GAA, GLO1, GSK3B, HSD17B10, IGF1R, KDR, MAPK1, MAPT, MET, MMP2, NMUR2, NPSR1, PIK3CA, PIK3CB, PIK3R1, PIM1, PKN1, PTK2, PTPN1, SLC6A2, SRC, TDP1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.376E-07 | 1.506E-05 | ADRA2A, AURKB, CA2, CA7, HIF1A, HTT, KDR, MAPK1, NEK2, NPSR1, PIK3CB, PLA2G1B, PTGS2, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.471E-07 | 1.585E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 2.084E-07 | 2.161E-05 | IGF1R, PIK3CA, PIK3CB, PIK3R1 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.028E-07 | 3.039E-05 | AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.114E-07 | 3.110E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.882E-07 | 4.663E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.877E-07 | 6.427E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 7.193E-07 | 6.665E-05 | ALK, CDK1, DRD4, MAPK1, PIK3CB, PKN1, PLA2G1B, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.127E-06 | 1.014E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.142E-06 | 1.019E-04 | AXL, MET, NOX4, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.207E-06 | 1.064E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.296E-06 | 1.127E-04 | CYP1A1, CYP2C8, CYP3A4 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.921E-06 | 1.603E-04 | AKT1, APEX1, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3B, HKDC1, HSD17B10, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, PKM, SRC, TP53 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.006E-06 | 1.661E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.583E-06 | 2.075E-04 | CYP1A1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 4.906E-06 | 3.646E-04 | ACHE, ALDH1A1, IGF1R, NQO2, PIK3R1, PKM |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 5.252E-06 | 3.825E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0051179; localization | GO:0046903; secretion | 5.401E-06 | 3.920E-04 | ALOX5, APP, AXL, CA2, CA9, CXCR1, DRD4, GAA, HIF1A, MAPK1, MMP9, MPO, NFKB1, NMUR2, PKM, PLA2G1B, PYGL, XDH |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 6.842E-06 | 4.885E-04 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 7.178E-06 | 5.075E-04 | ADRA2A, ADRA2C, DRD4 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 9.356E-06 | 6.509E-04 | AKT1, HIF1A, MMP9, PTGS2, PTPN1, SRC |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.209E-05 | 8.053E-04 | AKT1, MAPT, PTPN1, TP53 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.355E-05 | 8.913E-04 | AKT1, CYP1B1, DAPK1, GSK3B, HTT, MAPT, MMP9, NOX4, PIK3CB, PTGS2, SRC, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 1.380E-05 | 9.022E-04 | AKR1B1, AKT1, ALDH1A1, GAA, HKDC1, PIK3CA, PKM |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 1.416E-05 | 9.206E-04 | AKT1, ALOX15, AXL, CXCR1, NFKB1, NOX4, PIK3CA, PIK3CB, POLB, PTGS1, PTGS2 |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.489E-05 | 9.623E-04 | GSK3B, KDR, PIK3CB, PIK3R1, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.400E-26 | 8.057E-22 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.574E-05 | 1.005E-03 | AKT1, HIF1A, LMNA, PTGS2, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.837E-05 | 1.146E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.952E-05 | 1.208E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, NQO2, XDH |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.068E-05 | 1.268E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.091E-05 | 1.276E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 2.092E-05 | 1.276E-03 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.600E-05 | 1.514E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.600E-05 | 1.514E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.600E-05 | 1.514E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.600E-05 | 1.514E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.600E-05 | 1.514E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 2.675E-05 | 1.549E-03 | ADRA2A, ADRA2C, AKT1, SRC |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.778E-05 | 1.596E-03 | ESR1, MAPK1, STAT6 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 2.970E-05 | 1.680E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 3.365E-05 | 1.889E-03 | AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AURKB, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, FLT3, GFER, GLO1, GSK3B, HIF1A, HKDC1, HTT, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, NQO2, PIK3CA, PIK3CB, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PTPN1, PYGL, SRC, STAT6, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 3.524E-05 | 1.973E-03 | ADRA2A, AKT1, APP, CDK1, DAPK1, GSK3B, MAPT, PTK2, SRC, XDH |
| BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 3.717E-05 | 2.065E-03 | APP, CA2, CA7, DRD4, MAPK1, PTGS2 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 3.889E-05 | 2.128E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.424E-05 | 2.391E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 4.424E-05 | 2.391E-03 | AKR1B1, AKT1, MMP2, MMP9, PTGS2 |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 4.563E-05 | 2.447E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 5.302E-05 | 2.778E-03 | AKT1, APP, AXL, CA2, HIF1A, MAPK1, MMP2, NFKB1, PIK3CA, PIK3CB, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, TP53 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 5.332E-05 | 2.778E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 5.558E-05 | 2.882E-03 | MAPK1, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 6.914E-05 | 3.461E-03 | ADRA2C, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, MAPT, NFKB1, PIM1, PTGS2, SRC, STAT6 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 6.967E-05 | 3.464E-03 | PIK3CA, PTK2, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 7.530E-05 | 3.710E-03 | AKT1, HIF1A, KDR, PTGS2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.775E-05 | 3.755E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 7.775E-05 | 3.755E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 7.775E-05 | 3.755E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 7.775E-05 | 3.755E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 7.775E-05 | 3.755E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 7.775E-05 | 3.755E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 8.232E-05 | 3.948E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.429E-05 | 4.007E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.429E-05 | 4.007E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 8.429E-05 | 4.007E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 8.965E-05 | 4.215E-03 | ALPL, AXL, CYP1A1, CYP1A2, MPO, NFKB1, PTGS2, SRC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 9.777E-05 | 4.559E-03 | CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, SRC |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 9.778E-05 | 4.559E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.066E-04 | 4.927E-03 | AXL, CSNK2A1, DRD4, ESR1, GSK3B, SRC, TP53, USP2 |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.321E-04 | 6.007E-03 | APP, BACE1, KDR, MAPK1, PTGS2, SLC6A2, SRC, STAT6 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.550E-04 | 6.790E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.550E-04 | 6.790E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.550E-04 | 6.790E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.550E-04 | 6.790E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.550E-04 | 6.790E-03 | ESR1, ESR2 |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.624E-04 | 7.031E-03 | CA2, PTGS2, SRC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.624E-04 | 7.031E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 1.635E-04 | 7.056E-03 | ADRA2A, CAMK2B, DRD4, HTT, NPSR1, PLA2G1B, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 1.687E-04 | 7.259E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.740E-04 | 7.473E-03 | ADRA2A, AKT1, APEX1, APP, AURKB, CDK1, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, GSK3B, HIF1A, IGF1R, MAPT, MET, MMP3, MMP9, NFKB1, PIK3CA, PKN1, PTGS2, PTPN1, SRC, STAT6, TP53, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0010508; positive regulation of autophagy | 1.796E-04 | 7.698E-03 | DAPK1, HIF1A, HTT, KDR, PIK3CB |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.868E-04 | 7.922E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, NQO2, XDH |
| BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 1.874E-04 | 7.922E-03 | ESR1, ESR2, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.880E-04 | 7.933E-03 | AKT1, DAPK1, HTT, LMNA, SRC |
| BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.901E-04 | 8.005E-03 | AURKB, CDK1, HTT, LMNA, MAPT, NEK2, NEK6, PTK2 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.077E-04 | 8.697E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, CAMK2B, FLT3, MAPT, NFKB1, NQO2, PTGS2, PYGL, XDH |
| BP | GO:0009987; cellular process | GO:0032461; positive regulation of protein oligomerization | 2.147E-04 | 8.870E-03 | MMP1, MMP3, TP53 |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 2.147E-04 | 8.870E-03 | DRD4, NMUR2, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.147E-04 | 8.870E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 2.203E-04 | 9.066E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB |
| BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 2.349E-04 | 9.619E-03 | GSK3B, HIF1A, HTT, KDR, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 2.444E-04 | 9.967E-03 | CYP19A1, CYP1B1, HSD17B2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.039E-18 | 6.618E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.955E-17 | 3.547E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.748E-14 | 5.737E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.578E-25 | 1.250E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.774E-15 | 3.585E-13 | CAMK2B; SRC; MMP2; PIK3R1; PIK3CB; HIF1A; ESR1; MMP9; PTK2; IGF1R; PIK3CA; KDR; AKT1; MAPK1; TP53; MET |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.524E-14 | 1.599E-12 | PKM; PIK3CA; FLT3; HKDC1; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; MET; HIF1A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.034E-13 | 4.291E-11 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3CB; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; PIK3CA; AKT1; MAPK1; MET; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.307E-12 | 8.767E-11 | GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.590E-12 | 2.720E-10 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.726E-11 | 4.684E-10 | PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3CB; PIK3R1; PTGS2; PTK2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.011E-11 | 4.775E-10 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.008E-11 | 1.268E-09 | PIK3CA; SRC; MMP2; AKT1; MAPK1; PIK3R1; PIK3CB; ESR1; MMP9; ESR2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.951E-11 | 1.546E-09 | CAMK2B; PIK3CA; HKDC1; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A; NFKB1; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.479E-10 | 5.346E-09 | GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; ESR1; HIF1A |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.658E-10 | 5.346E-09 | PIK3CA; FLT3; PIM1; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.645E-10 | 7.151E-09 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.593E-10 | 6.233E-09 | CAMK2B; GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PIK3R1; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.082E-09 | 1.285E-08 | CAMK2B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.819E-09 | 2.819E-08 | PIK3CA; SRC; AKT1; MAPK1; STAT6; PIK3R1; PIK3CB; TP53; MMP9; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.564E-09 | 4.597E-08 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; CYP2C8; PKM; ALOX5; HKDC1; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPL; XDH |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.225E-09 | 2.349E-08 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; MET; IGF1R |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.787E-09 | 3.598E-08 | PIK3CA; MMP3; AKT1; MAPK1; PIK3R1; PIK3CB; PTGS2; MMP9; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 4.931E-09 | 4.259E-08 | GSK3B; PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3R1; PIK3CB; MET; PTK2; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.381E-11 | 1.546E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.356E-08 | 8.886E-08 | GSK3B; PIK3R1; PIK3CB; PTK2; NFKB1; IGF1R; PIK3CA; KDR; AKT1; MAPK1; PKN1; TP53; MET |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.189E-09 | 5.984E-08 | CAMK2B; GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.150E-09 | 1.285E-08 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.928E-09 | 4.259E-08 | ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.044E-08 | 7.349E-08 | PIK3CA; AKT1; PIK3CB; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.043E-08 | 1.807E-07 | GSK3B; PIK3CA; CXCR1; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PTK2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.548E-09 | 5.183E-08 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.743E-08 | 2.032E-07 | PIK3CA; MMP2; PIM1; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.130E-09 | 5.419E-08 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.971E-08 | 1.807E-07 | PTPN1; GSK3B; PIK3CA; HKDC1; AKT1; MAPK1; PIK3R1; PIK3CB; PYGL |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.246E-08 | 3.570E-07 | POLB; PKM; PIK3CA; SRC; CDK1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.117E-08 | 7.579E-08 | ALK; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.812E-08 | 3.570E-07 | PTPN1; GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; PYGL; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.312E-08 | 1.464E-07 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.877E-07 | 8.492E-07 | PIK3CA; PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; PIK3CB; MET; NFKB1; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.602E-08 | 2.013E-07 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.602E-08 | 2.013E-07 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; MET; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.327E-08 | 3.570E-07 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.327E-08 | 3.570E-07 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.441E-07 | 6.678E-07 | ABCC1; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.738E-07 | 1.210E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.188E-07 | 1.377E-06 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.783E-07 | 1.562E-06 | GSK3B; PIK3CA; CSNK2A1; AKT1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.722E-07 | 1.831E-06 | PIK3CA; LMNA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 7.229E-07 | 2.641E-06 | GSK3B; CSNK2A1; PIK3CA; CDK1; AKT1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.040E-06 | 3.592E-06 | PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3R1; PIK3CB; MET; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.230E-07 | 1.674E-06 | PIK3CA; AKT1; PIK3CB; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.625E-07 | 2.096E-06 | PIK3CA; CDK1; AKT1; MAPK1; PIK3R1; PIK3CB; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.178E-06 | 6.897E-06 | ABCC1; PIK3CA; PIM1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; MET; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.311E-06 | 4.369E-06 | CAMK2B; ACHE; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 8.432E-07 | 2.967E-06 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.978E-06 | 6.370E-06 | PIK3CA; ALOX5; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.473E-06 | 7.578E-06 | PIK3CA; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; PTGS1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.355E-07 | 1.417E-06 | PIK3CA; AKT1; PIK3CB; PIK3R1; PTGS2; PTGS1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 6.771E-06 | 2.010E-05 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; IGF1R |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.361E-05 | 3.804E-05 | CAMK2B; PIK3CA; SRC; MAPK1; PIK3R1; PIK3CB; PTGS2 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.309E-07 | 6.219E-07 | PKM; PIK3CA; HKDC1; MAPK1; PIK3CB; PIK3R1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 9.202E-06 | 2.690E-05 | CAMK2B; PIK3CA; SRC; ALOX12; PIK3R1; PIK3CB |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.091E-07 | 1.935E-06 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1; HIF1A |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.949E-05 | 5.217E-05 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; ADRA2C; ADRA2A |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.095E-05 | 3.151E-05 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.635E-05 | 6.830E-05 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.445E-05 | 3.978E-05 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 4.281E-05 | 1.056E-04 | POLB; GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; TP53; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.295E-05 | 3.673E-05 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.782E-06 | 5.837E-06 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.234E-07 | 2.952E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.431E-06 | 7.573E-06 | PIK3CA; SRC; PIK3CB; PIK3R1; MET; PTK2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.149E-07 | 1.674E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.971E-05 | 1.401E-04 | CAMK2B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.176E-06 | 3.991E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.000E-05 | 1.202E-04 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.660E-05 | 6.830E-05 | PIK3CA; MMP2; PIK3R1; PIK3CB; MMP9; PTK2 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 8.113E-05 | 1.880E-04 | PIK3CA; CXCR1; AKT1; MAPK1; PIK3R1; PIK3CB |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 9.440E-05 | 2.161E-04 | CAMK2B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 5.215E-05 | 1.239E-04 | PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; IGF1R |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.054E-04 | 2.357E-04 | GSK3B; PIK3CA; AKT1; PIK3R1; PIK3CB; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.352E-04 | 2.987E-04 | PIK3CA; PIM1; AKT1; STAT6; PIK3R1; PIK3CB |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 6.858E-04 | 1.386E-03 | PIK3CA; SRC; MAPK1; PIK3R1; PIK3CB; PTK2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.889E-04 | 4.078E-04 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 8.772E-03 | 1.558E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 9.343E-03 | 1.614E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.923E-03 | 3.767E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.446E-03 | 9.950E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 4.557E-03 | 8.488E-03 | PIK3CA; MAPK1; PIK3R1; PIK3CB |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 3.795E-04 | 7.923E-04 | PIK3CA; AKT1; PIK3R1; PIK3CB; IGF1R |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.270E-03 | 6.276E-03 | CAMK2B; CDK1; MAPK1; IGF1R |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.350E-02 | 2.192E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.667E-03 | 6.968E-03 | GSK3B; MAPK1; MET; PTK2 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.550E-04 | 9.295E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 3.177E-02 | 4.830E-02 | CSNK2A1; SRC; AKT1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 9.884E-05 | 2.236E-04 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.597E-03 | 3.162E-03 | CAMK2B; PKM; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.393E-04 | 3.043E-04 | PIK3CA; PIK3R1; PIK3CB; NFKB1; PTK2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.371E-02 | 3.724E-02 | GSK3B; CDK1; TP53 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.186E-05 | 5.768E-05 | PIK3CA; AKT1; MAPK1; PIK3CB; PIK3R1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.346E-02 | 2.192E-02 | CAMK2B; GSK3B; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.086E-03 | 2.172E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 1.275E-02 | 2.106E-02 | PIK3CA; PIK3R1; PIK3CB |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.107E-02 | 1.861E-02 | CSNK2A1; PTGS2; NFKB1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.624E-05 | 4.407E-05 | PIK3CA; AKT1; PIK3CB; PIK3R1; IGF1R |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.527E-03 | 1.631E-02 | SRC; CDK1; MAPK1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.088E-05 | 7.824E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.948E-03 | 1.574E-02 | MAPK1; PKN1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.695E-03 | 1.028E-02 | MAPK1; PTGS2; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.271E-03 | 9.723E-03 | CA2; CYP3A4; ABCG2 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.115E-03 | 7.741E-03 | SRC; MAPK1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.608E-04 | 7.618E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.245E-02 | 4.894E-02 | MAPK1; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 3.039E-02 | 4.656E-02 | GSK3B; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 2.697E-03 | 5.228E-03 | GAA; HKDC1; PYGL |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.453E-02 | 3.789E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.803E-06 | 8.453E-06 | PIK3CA; HKDC1; AKT1; PIK3CB; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.180E-02 | 3.451E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.005E-02 | 3.201E-02 | ABCC1; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 4.067E-05 | 1.017E-04 | PIK3CA; MAPK1; PIK3CB; PIK3R1 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.674E-02 | 2.696E-02 | PKM; GLO1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.027E-03 | 1.574E-02 | MAPK1; TP53 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.092E-02 | 1.853E-02 | HKDC1; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.159E-02 | 1.932E-02 | POLB; APEX1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.502E-05 | 1.097E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.335E-04 | 8.952E-04 | GAA; HKDC1; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.735E-03 | 1.028E-02 | CA2; CA4 |
| hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 2.451E-02 | 3.789E-02 | HKDC1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.402E-04 | 5.128E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; MMP1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; NQO2; IGF1R; CYP19A1; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C; SLC6A2 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; PIK3CB |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; SLC6A2; CYP3A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; SLC6A2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; GSK3B |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; PTGS1; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CDK1; ADRA2C; ADRA2A; SLC6A2; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; PTGS2; KDR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; NFKB1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; PTGS2; ADRA2C |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; PTK2; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2; MMP1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; PIK3CA; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; PIK3CB; KDR; KDR; KDR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; CSNK2A1; PIK3CA; FLT3; FLT3; CA9; MMP2; NQO2; ACHE; PTGS2; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TP53; PIK3CB; ESR1; ESR1; CA1; KDR; APP |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |